1. Benbow SJ, Cossins L, Mac Farlane IA. Painful diabetic neuropathy. Diabet Med 1999; 16: 632–44.
2. Boulton AJ, Vinik AI, Arezzo JC et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005; 28: 956–62.
3. Строков И.А., Пегасова О.М., Моргоева Ф.Э. Клиника и лечение болевых форм диабетической полиневропатии. Рос. мед. журн. 2004; 2: 23–7.
4. Benbow SJ, Chan AW, Bowsher D et al. Aprospective study of painful symptoms, small-fibre function and peripheral vascular disease in chronic painful diabetic neuropathy. Diabet Med 1994; 11: 17–21.
5. Daousi C, MacFarlane IA, Woodward A et al. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med 2004; 21: 976–82.
6. Kastenbauer T, Irsigler P, Sauseng S et al. The prevalence of symptoms of sensorimotor and autonomic neuropathy in Type 1 and Type 2 diabetic subjects. J Diabetes Complications 2004; 18: 27–31.
7. Belgrade MJ, Cole BE, McCarberg BH, McLean MJ. Diabetic peripheral neuropathic pain: case studies. Mayo Clin Proc 2006; 81 (Suppl.): S26–32.
8. Dworkin RH. An overview of neuropathic pain: syndromes, symptoms, signs, and several mechanisms. Clin J Pain 2002; 18: 343–9.
9. Boulton AJM, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care 2004; 27: 1458–86.
10. Harris MI, Eastman R, Cowie C. Symptoms of sensory neuropathy in adults with NIDDM in the U.S. population. Diabetes Care 1993; 16: 1446–52.
11. Robinson LR, Stolov WC, Rubner DE et al. Height is an independent risk factor for neuropathy in diabetic men. Diabetes Res Clin Pract 1992; 16: 97–102.
12. Sorensen L, Molyneaux L, Yue DK. Insensate versus painful diabetic neuropathy: the effects of height, gender, ethnicity and glycaemic control. Diabetes Res Clin Pract 2002; 57: 45–51.
13. Sumner CJ, Sheth S, Griffin JW et al. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 2003; 60: 108–11.
14. Franklin GM, Kahn LB, Baxter J et al. Sensory neuropathy in non-insulin-dependent diabetes mellitus. The San Luis Valley Diabetes Study. Am J Epidemiol 1990; 131: 633–43.
15. Novella SP, Inzucchi SE, Goldstein JM. The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy. Muscle Nerve 2001; 24: 1229–31.
16. Putz Z, Tabák AG, Tóth N et al. Noninvasive evaluation of neural impairment in subjects with impaired glucose tolerance. Diabetes Care 2009; 32: 181–3.
17. Dworkin RH. An overview of neuropathic pain: syndromes, symptoms, signs, and several mechanisms. Clin J Pain 2002; 18: 343–9.
18. Махинов К.А., Чурюканов М.В. Психологические особен­ности пациентов с болевой формой диабетической поли­нев­ропатии. Рос. журн. боли. 2014; 1: 74.
19. Lanting P, Faes TJ, Cliff GA et al. Autonomic and somatic peripheral nerve function and the correlation with neuropathic pain in diabetic patients. J Neurol Sci 1989; 94: 307–17.
20. Sorensen L, Molyneaux L, Yue DK. The relationship among pain, sensory loss, and small nerve fibers in diabetes. Diabetes Care 2006; 29: 883–7.
21. Britland ST, Young RJ, Sharma AK, Clarke BF. Association of painful and painless diabetic polyneuropathy with different patterns of nerve fiber degeneration and regeneration. Diabetes 1990; 39: 898–908.
22. Spruce MC, Potter J, Coppini DV. The pathogenesis and management of painful diabetic neuropathy: a review. Diabet Med 2003; 20: 88–98.
23. Attal N, Bouhassira D. Mechanisms of pain in peripheral neuropathy. Acta Neurol Scand (Suppl.) 1999; 173: 12–24.
24. Строков И.А., Новосадова М.В., Баринов А.Н., Яхно Н.Н. Клинические методы оценки тяжести диабетической полинейропатии. Неврол. журн. 2000; 5: 14–9.
25. Guastella V, Mick G. Strategies for the diagnosis and treatment of neuropathic pain secondary to diabetic peripheral sensory polyneuropathy. Diabet Metab 2009; 35: 12–9.
26. Freynhagen R, Baron R. The evaluation of neuropathic components in low back pain. Curr Pain Headache Rep 2009; 13: 185e90.
27. Walsh J et al. Agreement and correlation between the self-report leeds assessment of neuropathic symptoms and signs and douleur neuropathique 4 questions neuropathic pain screening tools in subjects with low back-related leg pain. J Manipulative Physiol Ther 2012; 35 (3): 196–202.
28. Smart KM et al. Mechanisms-based classifications of musculoskeletal pain: Part 2 of 3: Symptoms and signs of peripheral neuropathic pain in patients with low back (±leg) pain/Manual Therapy 2012; 17: 345e351.
29. Treede RD, Jensen TS, Campbell JN et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008; 70: 1630–5.
30. Shy ME, Frohman EM, So YT et al. Quantitative sensory testing: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003; 60: 898–904.
31. Hartemann A, Attal N, Bouhassira D. Painful diabetic neuropathy: Diagnosis and management. Diabet Metab 2011; 37: 377–88.
32. Norgren L, Hiatt WR, Dormandy JA et al. TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007; 45: S5–67.
33. Horowitz SH. The diagnostic workup of patients with neuropathic pain. Med Clin North Am 2007; 91: 21–30.
34. Siebert E, Prüss H, Klingebiel R et al. Lumbar spinal stenosis: syndrome, diagnostics and treatment. Nat Rev Neurol 2009; 5: 392–403.
35. Merlino G, Valente M, Serafini A, Gigli GL. Restless legs syndrome: diagnosis, epidemiology, classification and consequences. Neurol Sci 2007; 28: S37–46.
36. Airey M, Bennett C, Nicolucci A, Williams R. Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy. Cochrane Database Syst Rev 2007; 3: CD002182.
37. Rowbotham MC. Mechanisms of neuropathic pain and their implications for the design of clinical trials. Neurology 2005; 65 (Suppl. 4): S66–73.
38. Dworkin RH, O’Connor AB, Backonja M et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007; 132: 237–51.
39. Moulin DE, Clark AJ, Gilron I et al for the Canadian Pain Society. Pharmacological management of chronic neuropathic pain – consensus statement and guidelines from the Canadian Pain Society. Pain Res Manage 2007; 12: 13–21.
40. Attal N, Cruccu G, Haanpää M et al for the EFNS Task Force. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur
 J Neurol 2006; 13: 1153–69.
41. Oxford Centre for Evidence-based Medicine. Levels of evidence and grades of recommendation, 2009; http://www.cebm.net/ index.aspx?o=1025
42. Gilron I, Bailey JM, Tu D et al. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet 2009; 374: 1252–61.
43. Bansal D, Bhansali A, Hota D et al. Amitriptylinevs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial. Diabet Med 2009; 26: 1019–26.
44. Kaur H, Hota D, Bhansali A et al. A comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: a randomized, double-blind, cross-over clinical trial. Diabetes Care 2011; 34: 818–22.
45. Jose VM, Bhansali A, Hota D, Pandhi P. Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy. Diabet Med 2007; 24: 377–83.
46. Quilici S, Chancellor J, Löthgren M et al. Metaanalysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurol 2009; 9 (6).
47. Mailis-Gagnon A, Furlan AD, Sandoval JA, Taylor R. Spinal cord stimulation for chronic pain. Cochrane Database Syst Rev 2004; 3: CD003783.
48. Ziegler D. Treatment of diabetic polyneuropathy. Ann NY Acad Sci 2006; 1084: 250–66.
49. Derry S, Lloyd R, Moore RA, McQuay HJ. Topical capsaicin for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2009; 4: CD007393.

М.В.Чурюканов

Кафедра нервных болезней и нейрохирургии ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава России